Nature Reviews Neurology - Table of Contents alert Volume 11 Issue 6

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
June 2015 Volume 11 Number 6
Impact Factor 14.103 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Vascular parkinsonism—characteristics, pathogenesis and treatment Amos D. Korczyn
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
An open access journal dedicated to highlighting the most important scientific advances in Parkinson's disease research, spanning the motor and non-motor disorders of Parkinson's disease. Part of the Nature Partner Journals series, npj Parkinson's Disease is published in partnership with the Parkinson's Disease Foundation. Open for submissions: http://bit.ly/1uUh8YB
Advertisement
Nature Communications is now fully open access All new submissions if accepted, will be published open access and an article processing charge will apply. For more information visit the website. Visit our open access funding page or contact openaccess@nature.com to learn more on APC funding.
RESEARCH HIGHLIGHTS Top Alzheimer disease: The involvement of TREM2 R47H variant in Alzheimer disease confirmed, but mechanisms remain elusive Published online: 19 May 2015 p307 | doi:10.1038/nrneurol.2015.84 PDF Motor neuron disease: Can gluten sensitivity mimic amyotrophic lateral sclerosis? Published online: 28 April 2015 p308 | doi:10.1038/nrneurol.2015.75 PDF Neuromuscular disease: Improved diagnostic sensitivity can aid the correct choice of treatment for patients with myasthenia gravis Published online: 05 May 2015 p308 | doi:10.1038/nrneurol.2015.78 PDF Traumatic brain injury: Structural changes can progress for months after brain injury Published online: 26 May 2015 p309 | doi:10.1038/nrneurol.2015.83 PDF Neurodegenerative disease: Tau is linked to cognitive decline in Huntington disease Published online: 26 May 2015 p310 | doi:10.1038/nrneurol.2015.87 PDF IN BRIEF Neuro-oncology: Exosomal mRNA might provide a biomarker for treatment response in patients with glioblastoma | Movement disorders: Inhibition of the tyrosine kinase Src might be a new strategy for treating Friedreich ataxia | Stroke: Overlap between the genetic loci that confer risk of migraine and ischaemic stroke | Multiple sclerosis: Vitamin D supplementation might be most protective against multiple sclerosis when taken during adolescence | Stroke: Desmoteplase is not an effective late treatment for stroke | Epilepsy: Children with status epilepticus can face considerable delays before receiving effective antiseizure treatment | Neurodevelopmental disorders: Inherited truncating mutations and copy number variants are common in children with autism spectrum disorders | Parkinson disease: Little evidence for efficacy of rasagiline for depression in patients with Parkinson disease PDF Neurology JOBS of the week Chair, Department of Neurology University of California Los Angeles Full Professor (W3) / Chair of Neurology Universitat Heidelberg Post-doctoral fellow in Modeling of Frontotemporal Dementia using iPSC KU Leuven Postdoctoral position in theoretical graph analysis of brain connectivity Istituto Italiano di Tecnologia (IIT) Epileptologist and Human Brain Neurophysiologist Duke University School of Medicine More Science jobs from Neurology EVENT 22nd World Congress of Neurology 31.10.15 Santiago, Chille More science events from
NEWS AND VIEWS		Top
Epilepsy: Neonatal seizures still lack safe and effective treatment Marianne Thoresen & Hemmen Sabir Published online: 28 April 2015 p311 | doi:10.1038/nrneurol.2015.74 Seizures after neonatal hypoxia are difficult to treat. A recent antiepileptic safety and dose-finding study examined phenobarbital plus bumetanide, but was stopped owing to apparent futility and increased risk of hearing loss. However, this decision could have been overcautious: 0.2 mg/kg bumetanide reduced seizure burden, and might not have increased hearing loss. Full Text | PDF
Multiple sclerosis: Genetic variability affects CNS IgG production in MS Jose C. Álvarez-Cermeño & Luisa M. Villar Published online: 14 April 2015 p313 | doi:10.1038/nrneurol.2015.55 Local synthesis of IgG in the CNS is present in >90% of patients with multiple sclerosis (MS), and is considered a hallmark of the disease. A recent study has discovered genetic factors associated with intrathecal production of these antibodies, and suggests excessive IgG synthesis as an indicator of an aggressive disease. Full Text | PDF
Neuro-oncology: Primary CNS lymphoma treatment—the devil is in the details Lisa M. DeAngelis Published online: 05 May 2015 p314 | doi:10.1038/nrneurol.2015.64 Primary CNS lymphoma (PCNSL) is uniquely responsive to initial radiotherapy or chemotherapy, but the best therapeutic approach remains uncertain. Recently updated results from a phase III trial do not support the use of radiotherapy in PCNSL, although the analyses had several disappointing limitations. Full Text | PDF
Multiple sclerosis: Switching sides—fingolimod versus injectable MS therapies Ian T. Rossman & Jeffrey A. Cohen Published online: 21 April 2015 p316 | doi:10.1038/nrneurol.2015.59 A new study shows that in patients with multiple sclerosis who exhibit active disease despite disease-modifying therapy, a switch to fingolimod is more effective than continuation of IFN-β or glatiramer acetate for preventing relapses and worsening of disability. These data support the utility of treatment escalation to improve disease control. Full Text | PDF
REVIEWS		Top
Vascular parkinsonism—characteristics, pathogenesis and treatment Amos D. Korczyn Published online: 28 April 2015 p319 | doi:10.1038/nrneurol.2015.61 Vascular parkinsonism can result from a variety of vascular disorders, and most frequently manifests as an impairment of gait known as lower body parkinsonism. In this Review, Amos Korczyn summarizes the current understanding of clinical and pathogenetic aspects of vascular parkinsonism, including knowledge gained from neuroimaging, and considers current and future therapy for this condition. He also considers whether similarities between vascular parkinsonism and Binswanger disease mean that they should be considered as manifestations of the same pathology. Abstract | Full Text | PDF
Spinal cord MRI in multiple sclerosis—diagnostic, prognostic and clinical value Hugh Kearney, David H. Miller & Olga Ciccarelli Published online: 26 May 2015 p327 | doi:10.1038/nrneurol.2015.80 MRI studies in multiple sclerosis (MS) have mainly focused on brain lesions because of the technical challenges in spinal cord imaging. However, spinal cord abnormalities correlate with disability in MS, and have important diagnostic and prognostic implications. This Review provides an update on technical advances in spinal cord MRI, and discusses the clinical relevance of recent insights into spinal cord pathology in MS. Abstract | Full Text | PDF | Supplementary information
Toward stem cell-based phenotypic screens for neurodegenerative diseases Vikram Khurana, Daniel F. Tardiff, Chee Yeun Chung & Susan Lindquist Published online: 19 May 2015 p339 | doi:10.1038/nrneurol.2015.79 Despite the increasing prevalence of neurodegenerative diseases in our ageing population, disease-modifying therapies remain elusive. As the mechanisms underlying neurodegeneration are poorly understood, these diseases are not especially amenable to target-based drug screening strategies. Here, Khurana et al. present phenotypic screening as an alternative drug discovery approach, and discuss how insights from a simple eukaryote, baker's yeast, are driving research in patient-derived neurons. Abstract | Full Text | PDF
Spinal muscular atrophy—recent therapeutic advances for an old challenge Irene Faravelli, Monica Nizzardo, Giacomo P. Comi & Stefania Corti Published online: 19 May 2015 p351 | doi:10.1038/nrneurol.2015.77 Spinal muscular atrophy (SMA) is the most common genetic cause of infant death. No disease-modifying treatments are available for SMA, but the increasingly precise understanding of SMA aetiopathogenesis has led to the development of promising therapeutic strategies. Here, Farevelli et al. provide an overview of established data and novel insights into SMA pathogenesis, and discuss preclinical evidence and recent advances from ongoing clinical trials. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION FTD and ALS—translating mouse studies into clinical trials Lars M. Ittner, Glenda M. Halliday, Jillian J. Kril, Jürgen Götz, John R. Hodges & Matthew C. Kiernan Published online: 05 May 2015 p360 | doi:10.1038/nrneurol.2015.65 The symptoms and neuropathology of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) can show a high degree of overlap, and few effective treatments exist for these conditions. In this Perspectives article, Ittner and colleagues describe recent failures in the translation of data from mouse models into clinical trials for patients with FTD and/or ALS. The authors summarize the strengths and weaknesses of several available mouse models, and make recommendations for improving future research practice. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2013. Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.